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2Abstract17
Objective. To evaluate the national antenatal syphilis screening programme and provide evidence18
for improving screening and management strategies.19
Design. National population-based surveillance.20
Setting. United Kingdom (UK).21
Population. All pregnant women screening positive for syphilis, 2010-2011.22
Methods. Demographic, laboratory and treatment details for each pregnancy were collected from23
UK antenatal units (~210), along with follow up information on all infants born to women requiring24
syphilis treatment in pregnancy.25
Main outcome measures. Proportion of women with newly or previously diagnosed syphilis among26
those with positive screening tests in pregnancy; proportion requiring treatment.27
Results. Overall 77% (1425/1840) of reported pregnancies were confirmed syphilis screen-positive.28
Of these, 71% (1010/1425) were in women with previously diagnosed syphilis (155 requiring29
treatment), 26% (374/1425) with newly diagnosed syphilis (all requiring treatment) and 3%30
(41/1425) required treatment but the reason was unclear. Thus 40% (570/1425) required treatment31
overall; of these, 96% (516/537) were treated (missing data: 33/570), although for 18% (83/456),32
this was not until the third trimester (missing data: 60/537). Follow up of infants born to treated33
women was poor, with at least a third not followed. Six infants were diagnosed with congenital34
syphilis; two mothers were untreated, three had delayed treatment and one incomplete treatment35
(first trimester).36
Discussion. Over two years, among pregnant women with confirmed positive syphilis screening37
results in the UK, a quarter had newly diagnosed infections and two fifths required treatment.38
Despite high uptake of treatment, antenatal syphilis management could be improved by earlier39
detection, earlier treatment, and stronger links between healthcare teams.40
3Tweetable abstract. 25% of pregnant women screening positive for syphilis in the UK were newly41
diagnosed and 40% needed treatment.42
4Surveillance of antenatal syphilis screening in the United Kingdom, 2010-201143
Introduction44
Syphilis in pregnancy remains a global public health problem, with approximately 1.36 million45
women (range: 1.16-1.56 million) worldwide estimated to have active syphilis in pregnancy in 2008.146
Untreated syphilis infection is commonly associated with adverse pregnancy outcomes including47
miscarriage, stillbirth, preterm birth, hydrops and polyhydramnios,2 and can be transmitted to the48
fetus, leading to growth restriction, low birth weight, and long-term sequelae including hearing loss,49
neurological impairment and bone deformities.3 Congenital syphilis is almost entirely preventable,50
and the World Health Organization called for global elimination (less than 50 cases per 100 000 live51
births) by 2015, through testing of ≥95% of pregnant women and treatment of ≥95% of those 52
identified.4 In cases of early (primary, secondary, early latent) syphilis in pregnancy, treatment with a53
single intramuscular injection of benzathine penicillin G (2.4MU) is recommended, if administered in54
the first or second trimester of pregnancy, or two doses if administered later.5 Current British55
guidelines also advise re-treatment if there is uncertainty over the efficacy of past treatment.6 For56
late latent syphilis in pregnancy, three doses of benzathine penicillin are recommended.657
In the United Kingdom (UK), new diagnoses of infectious syphilis in women more than doubled58
between 1999 and 2007, and anecdotally sexual health clinics reported around 10 cases of59
congenital infection annually.7 Since a peak of around 500 in 2005, new diagnoses in women60
subsequently declined to 265 in 2012, although infections in men remain 10-fold higher, mainly due61
to ongoing transmission in men who have sex with men.862
Screening is routinely offered and recommended to all pregnant women in England,9 with uptake63
over 97%;10 in 2014, 0.14% of pregnant women (971/709,204) screened positive.10 However, a64
positive screening test can indicate current or past syphilis infection, or may be a false positive65
result, sometimes indicating a history of endemic treponemal infection such as yaws or pinta.66
Women screening positive for syphilis therefore need referral to an appropriate specialist (e.g. a67
5genitourinary (GU) physician) for clinical assessment based on a detailed medical history, physical68
examination, and laboratory results. Although uptake of screening is high, concerns have been69
raised about the subsequent investigation, treatment and follow up of screen-positive women and70
their babies.1171
The aim of this study was to evaluate the UK antenatal syphilis screening programme and provide72
evidence for improving screening and management strategies, by reviewing screen-positive73
pregnancies over a two-year period and assessing their management and outcome.74
75
Methods76
The Surveillance of Antenatal Syphilis Screening (SASS) study was a comprehensive national77
surveillance study through which information on all syphilis-positive pregnancies was requested78
from designated respondents in all maternity units in the UK. It was modelled on the National Study79
of HIV in Pregnancy and Childhood,12 and for 80% of units the respondent was the same individual.80
Study respondents were contacted every three months and asked to report all pregnancies in81
women attending for antenatal care in 2010-2011 with a positive syphilis screening test. Basic82
demographic, pregnancy and laboratory data were collected using a standard form. Respondents83
were asked to report whether screen-positive cases were classified as newly diagnosed or previously84
diagnosed syphilis infection (with or without history of adequate treatment), or false positive9 (e.g85
due to other treponemal infections, non-specific reactivity, or test errors), and to provide treatment86
details if it was required. Information on other positive screening tests in pregnancy (e.g. HIV,87
hepatitis B virus) was also collected. For pregnancies where treatment was required, outcome88
information was requested soon after the estimated date of delivery (EDD), along with details of the89
paediatrician responsible for infant follow-up; paediatricians were contacted between 2011 and90
2013, when infants were at least 6 months old, to identify cases of congenital syphilis. Duplicate91
reports were matched using maternal dates of birth and other identifiers (EDD, ethnicity, etc), as no92
6names were collected. A parallel paediatric study of congenital syphilis cases diagnosed between93
2010 and 2015 was carried out through the British Paediatric Surveillance Unit (BPSU) of the Royal94
College of Paediatrics and Child Health (www.rcpch.ac.uk/what-we-do/bpsu/current-95
studies/congenital-syphilis/congenital-syphilis). Cases of congenital syphilis reported through the96
two studies were matched using mothers’ and babies’ dates of birth and other identifiers, in order to97
ascertain any cases missed by either study.98
Maternal country of birth was grouped by United Nations region99
(http://unstats.un.org/unsd/methods/m49/m49regin.htm). Hospitals were grouped by UK country100
and English region using the National Health Service (NHS) Strategic Health Authorities in place at101
the time of the study. Setting of previous syphilis diagnosis (if relevant) was recorded as “Antenatal”102
(i.e. in a previous pregnancy) or “Other / Not known”. If date of booking for antenatal care (i.e. first103
antenatal appointment) was missing, the earliest syphilis test date was used as a proxy. Gestation at104
antenatal booking was calculated from booking date and EDD in most cases; where EDD was missing,105
it was estimated from delivery date and gestation at birth (n=59). The interval between antenatal106
booking and treatment was calculated from treatment date and booking date, or first test date if107
booking date was missing. Time since arrival in the UK for women born abroad was calculated as the108
difference between year of arrival and year of booking.109
Data were managed in Access 2010 (Microsoft Corp., Redmond, Washington, USA) and analysed110
using Stata version 12.1 (Stata Corp. LP, College Station, Texas, USA). Categorical variables were111
compared using χ2 tests or Fisher’s exact tests, and medians using Kruskal-Wallis tests. Analyses112
relate to pregnancies and some women (<3%) had more than one pregnancy reported during the113
study period. Preterm birth and low birthweight rates for the general population were obtained114
from Office for National Statistics data for the whole of England and Wales,13 and comparisons made115
using the one-sample test of proportions.116
117
7Results118
Response rates119
Ninety-eight percent of reporting cards were returned (total 1662/1697; on average 208/212 per120
reporting period). There were 2162 reports of syphilis screen-positive pregnancies, of which 223121
were excluded (Figure 1), leaving 1939 reports. Of these, 92% (1781/1939) were from England, 4%122
(84/1939) from Scotland, 3% (51/1939) from Northern Ireland, and 1% (23/1939) from Wales.123
Syphilis classification / diagnosis and baseline characteristics124
There was insufficient information to classify 5% of screen-positive pregnancies (99/1939) (Figure 1),125
mostly because they were lost to follow up (48/99), or resulted in miscarriage or termination126
(28/99), and no further details were available. Among 1840 classified pregnancies, 77% (1425) were127
confirmed positives (i.e. newly or previously diagnosed syphilis infection), the remainder being128
reported as “false positives” (Figure 1). Among confirmed positives, 26% (374/1425) of women were129
newly diagnosed with syphilis, and 71% (1010/1425) had a previous syphilis diagnosis; 3% (41/1425)130
were reported to require treatment but whether this was for a previously or newly diagnosed131
infection was unclear (Figure 1).132
Over half of the 1425 confirmed positive pregnancies were in European-born women (Table 1), of133
whom 39% (268/687) were born in Eastern Europe. Most women had previously been pregnant134
(Table 1), 88% (927/1058) of whom had previous live or still births. About 6% (81/1271) had their135
first antenatal appointment in the third trimester (at 27 weeks gestation or later), and 9% were136
reported to have screened positive for HIV, hepatitis B, and/or hepatitis C virus in pregnancy (Table137
1). In about 5% of confirmed positive pregnancies (76/1425), respondents spontaneously reported138
that women did not attend antenatal or genitourinary medicine (GUM) appointments, had poor139
adherence to syphilis treatment, and/or had complex or adverse social circumstances (e.g. drug or140
alcohol use, immigration or housing problems, domestic violence, prison); often these factors were141
8reported as reasons for problems with referral or follow up, or to explain why information was not142
available.143
There was wide variation by region in the proportion of false positives (23% overall, Figure 1), from144
less than 10% in about half of UK countries or regions, to 32% in London (270/849) and 56% in145
Scotland (46/82). Few false positives were reported as due to other treponemal infections (n<15).146
Previously diagnosed syphilis infection147
Among 1010 pregnancies in women with previously diagnosed syphilis, 31% (313/1010) overall and148
36% (290/816) of those with previous pregnancies were reported to have been diagnosed during an149
earlier pregnancy, a median of three years prior to the current booking (interquartile range (IQR): 2,150
5 years; n=283 overall). Most women with previously diagnosed syphilis (85%, 855/1010) were151
reported not to require treatment in the current pregnancy; however, treatment was advised for152
15% (Figure 1), mainly because of inadequate documentation of previous treatment (other reasons153
included: previous treatment incomplete, loss to follow-up or miscarriage before treatment could be154
offered in a previous pregnancy, and possible reinfection and/or positive EIA IgM test in the current155
pregnancy). Among women with previously diagnosed syphilis, 79% (711/898) were referred to a156
GUM clinic for assessment (information missing for 112/1010). Among 187 women who were not157
referred, possible reasons included miscarriage or termination (n=9), loss to follow up or lack of158
engagement with care (n=7) and multiple care providers (n=7). However, for most, no reason was159
given for lack of referral.160
Newly diagnosed syphilis infection161
All 374 women with newly diagnosed syphilis required treatment in pregnancy, and virtually all were162
referred to a GU physician (two women were not referred owing to difficult circumstances). Syphilis163
disease stage was reported for 73% (273/374) of these women: 14% (39/273) were reported to have164
9primary, 4% (12/273) secondary, 14% (38/273) early latent, 66% (181/273) late latent, and 1%165
(3/273) late symptomatic/tertiary infection.166
Treatment167
Overall, 40% of confirmed positive pregnancies (570/1425) were in women who required treatment168
for syphilis in pregnancy (Figure 1); 96% were reported to have received treatment but 21 women169
were not treated (Table 2). Most treated women (89%) were prescribed benzathine penicillin, and170
median gestation at treatment initiation was 17.4 weeks (IQR: 14.2, 23.8 weeks; n=456). Treatment171
occurred in the third trimester in 18% of pregnancies (Table 2), and was more likely to be delayed in172
women born in European countries outside the UK (26%, 32/124) than in UK-born women (12%,173
15/130, p=0.006). Median time since arrival in the UK among women born abroad was significantly174
shorter for those treated in the third trimester than for those treated in the first or second trimester175
(1 year, IQR: 0, 3 years, n=35, versus 3 years, IQR: 1, 7 years, n=113, p<0.001), but year of arrival was176
poorly reported (see Table 1). Among women treated in the third trimester, first antenatal177
appointment occurred at a median of 22.4 weeks (IQR: 13.0, 31.0 weeks, n=82), a median of 9.6178
weeks prior to treatment initiation (IQR: 2.7, 19.0 weeks).179
Among women receiving benzathine penicillin, 73% received at least three doses (Table 2), most of180
whom had late latent infection (66%, 209/318) or unreported disease stage (19%, 61/318). Eighty-181
eight percent of women with late latent syphilis (209/238) received three doses of benzathine182
penicillin, and 10 of 11 women with early syphilis treated in the third trimester received two or more183
doses. Among women with early syphilis infection who received benzathine penicillin before the184
third trimester, 81% (54/67) received more than one dose, even though guidelines suggest that one185
dose is sufficient. Seven of these were specifically reported to require additional doses (e.g. due to186
reinfection or treatment failure); half of the remainder (23/47) were classified as having early latent187
syphilis, which may be difficult to distinguish from late latent infection.188
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An additional five women were reported as having been treated during pregnancy although they did189
not require it (e.g. as a precaution due to late presentation or at patient request).190
According to routine data sources, 691,494 women were screened for syphilis antenatally in 2011 in191
England14; in our study, 851 women had confirmed syphilis and 244 of these required treatment192
during pregnancy (figures restricted to pregnancies in England in 2011). In other words, for each193
woman requiring treatment who was identified through the screening programme, approximately194
2800 women were screened for syphilis.195
Pregnancy outcomes among women requiring treatment196
Outcome details were sought for all 570 pregnancies in women reported to require treatment197
(Figure S1). There were 10 stillbirths; no evidence of congenital syphilis was found at post-mortem in198
five, including three where other causes were identified (e.g. congenital anomalies); for the other199
five no further details were available.200
Deliveries occurred between July 2010 and March 2012. Among the 477 pregnancies with201
information on delivery (including five twin births) (Figure S1), 10% were delivered by elective202
caesarean section (45/454), 21% (97/454) by emergency caesarean section, and 69% (312/454)203
vaginally. For singleton live births, the preterm delivery rate (<37 weeks gestation) was 8% (32/419;204
95% confidence interval (CI), 5-11%), similar to that in the general population (6.2% in England in205
2005, t-test p=0.22)13. Median birth weight was 3.3 kg (IQR: 3.0, 3.6 kg), and 10% of infants weighed206
<2.5 kg (41/431, 95% CI: 7%-13%), significantly higher than the general population (6.1% in England207
in 2005, t-test p=0.004)13.208
For 26% (125/482) of live born infants (including the five sets of twins), paediatric follow up forms209
were not returned. Furthermore, where forms were received, 18% (64/357) of infants were lost to210
follow up (e.g. moved away, failed to attend appointments, family declined follow up, etc), and211
another 15% (53/357) had no paediatric follow up, 20 reportedly because the mother had been212
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adequately treated. Among infants whose mothers had newly diagnosed syphilis in pregnancy, 15%213
(36/240) were lost to follow up and 8% (19/240) were reported not to have been followed up.214
Six infants born to women who required treatment in pregnancy were diagnosed with congenital215
syphilis: four of the mothers received incomplete and/or delayed treatment (one received partial216
treatment in the first trimester, and three were treated in the third trimester only), but two were217
untreated; four of the six infants were preterm. One additional infant, whose mother was reported218
to this study as previously diagnosed and adequately treated (therefore not followed up further) was219
subsequently reported to the BPSU study as having congenital syphilis, likely as a result of maternal220
reinfection.221
222
223
Discussion224
Main findings225
Over 1900 pregnancies in women screening positive for syphilis in pregnancy in 2010-2011 were226
reported in this UK study. Among the 1425 pregnancies with confirmed syphilis, about a quarter227
were in women with newly diagnosed infection, and over two thirds (71%) had a previous syphilis228
diagnosis; of the latter, most were seen by a GU physician, and about 15% were reported to have229
required treatment in pregnancy. Our findings suggested that among women with a previous syphilis230
diagnosis, about a third had been diagnosed in a previous pregnancy, reflecting the high uptake of231
antenatal screening over previous years.15 About 40% of confirmed syphilis-positive pregnancies232
were in women requiring treatment, two thirds due to a newly diagnosed infection, and 96% were233
treated. Most women with late latent syphilis infection (88%) received three doses of benzathine234
penicillin, in line with UK guidelines.235
236
12
Strengths and limitations237
This study was the first national evaluation of the antenatal syphilis screening programme in the UK.238
High response rates were achieved, and the number of pregnancies reported corresponded closely239
with the number expected for 2010-2011 based on routine data (~1000/year).10, 14 Despite good case240
ascertainment, miscarriages and pregnancy terminations in syphilis-positive women were probably241
under-ascertained, as the study only included women accessing antenatal care. In order to avoid242
missing cases, we invited respondents to report all syphilis screen-positive pregnancies including243
false positives; these accounted for almost a quarter of reports, with wide variation across the244
country, partly due to an incident involving IgM test kits used in some laboratories.16 We were also245
aware of differential reporting of false positive results by unit, with some respondents providing246
these figures and others not, an issue that may also arise in routine data sources.247
248
Interpretation249
This study suggested that for every case of syphilis identified and treated, about 2800 women were250
screened. Although this number may seem high, antenatal syphilis screening combined with251
treatment has been shown to be cost-effective even in low-to-moderate prevalence settings 17 and252
its high uptake (>97%) suggests that it is acceptable to pregnant women. Furthermore, the UK253
antenatal syphilis screening programme was reviewed in 2013, with a recommendation that254
screening should continue in light of ongoing transmission among women of reproductive age, and255
the balance of benefits to harm.18256
We identified 570 women requiring treatment for syphilis in pregnancy over two years (~285/year),257
at least two thirds with undiagnosed infection who would likely have remained untreated in the258
absence of screening, with a risk of onward transmission to their babies and sexual partners. In a259
previous survey among GU physicians, 139 similar cases were identified over three years (1994-260
1997, ~46/year), with 70% response rate (lower than in our study).19 Although methods differed (the261
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previous survey excluded women seen only by their obstetricians), the increase is in line with the262
rise in infectious syphilis in women observed since 1999. Although diagnostic and treatment263
information was obtained for most pregnancies, it was clear that links between maternity and GUM264
services were not always satisfactory. Contrary to national standards,9 key information on diagnosis265
and treatment was not always known to maternity teams, even after delivery, and despite repeated266
requests for information, 5% of confirmed screen-positive pregnancies remained unclassified.267
Although women with newly diagnosed infections were almost all referred to a specialist, about 20%268
of previously-diagnosed women were not, even though all screen-positive women should be269
evaluated by a GU physician;6, 9 in addition, basic information on whether referral had occurred was270
missing for 11%.271
Current UK management guidelines also recommend that infants born to women treated for syphilis272
during or before pregnancy should be monitored.6 This study showed that even infants with newly-273
diagnosed mothers were not always followed up. Where further appointments were planned, these274
were not always attended, suggesting issues around retention in care. Despite improvements in275
follow up of mothers and infants since earlier audits,11 our findings highlighted some inadequacies276
and inconsistencies in the management and follow up of pregnancies in syphilis-positive women,277
which could potentially lead to avoidable cases of congenital infection. Nevertheless, with routine278
screening in place and high uptake of testing (>97%) and treatment (96%), few cases of congenital279
syphilis were reported. The timely diagnosis and treatment of several hundred maternal infections280
will also have prevented other adverse pregnancy outcomes (reported to occur in approximately281
two-thirds of untreated pregnancies1) and transmission to sexual partners, neither of which were282
measured here.283
It was reassuring that over 95% of women reported to require treatment were treated, in line with284
WHO targets,4 but the fact that almost one in five women were treated in the third trimester was285
concerning, given the increased risk of adverse outcomes.20 Furthermore, three of the cases of286
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congenital syphilis were associated with delayed maternal treatment and two with lack of287
treatment. Treatment in the third trimester was associated with being born abroad and more recent288
arrival in the UK. However, over half of women treated in the third trimester experienced a delay of289
almost 10 weeks between first antenatal appointment and treatment initiation, and about a quarter290
had been in contact with antenatal services in the first trimester. These observations suggest that291
issues around both access to and engagement with care contributed to treatment delays. The292
finding that one in 11 syphilis-positive women screened positive for another blood-borne infection293
and one in 20 (a minimum estimate) had social issues or problems taking up care or treatment294
highlights the complex healthcare needs of this population. Furthermore, the prevalence of HIV in295
this population was high, at 4%, compared with 0.22% among all pregnant women in the UK in296
2011.21 The majority of syphilis-positive women in this study were from Eastern Europe, Africa or297
Asia, areas where historically the prevalence of syphilis has been much higher than in Western298
Europe, and coverage of antenatal testing and treatment much lower.1, 22299
Most women in this study should also have been tested for other sexually transmitted infections at300
their GUM appointment, but full details were not collected here. Although this study was carried out301
through antenatal clinics and therefore included few miscarriages and terminations, efforts should302
be made to follow up all pregnant women screening positive for syphilis regardless of pregnancy303
outcome, particularly as many women will have subsequent pregnancies. It was reassuring that the304
preterm delivery rate among women treated in pregnancy (8%) was not substantially higher than305
the general population, although infant birth weight was significantly lower,13 probably due to socio-306
demographic and other factors. For syphilis treatment before the third trimester, UK guidelines307
recommend a single dose of benzathine penicillin for women with early syphilis;6 however over308
three quarters of women with early syphilis in this study received two or more doses, possibly309
reflecting a precautionary approach to treatment.310
311
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Conclusions312
Despite high uptake of antenatal syphilis screening and treatment in the UK, this study has313
highlighted areas where management of syphilis could be improved, including earlier diagnosis and314
treatment of pregnant women, better communication between maternity and GUM services, and315
more consistent follow-up of exposed infants. Optimal care and management of syphilis-positive316
women in pregnancy requires a coordinated multidisciplinary approach involving antenatal, GUM317
and paediatric teams, to ensure that guidelines are followed, and testing, referral and treatment are318
not delayed.319
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Figure 1. Reports of syphilis screen-positive pregnancies in the UK, 2010-2011.a Includes 
those adequately treated requiring no further treatment, and those requiring treatment due 
to inadequate documentation of previous treatment (e.g. no previous treatment, 
incomplete or uncertain treatment) or suspected re-infection.  
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Figure S1. Follow up of women requiring treatment for syphilis in pregnancy, 2010-
2011. 
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1Table 1. Baseline characteristics of 1425 pregnancies in 1394 women with newly or
previously diagnosed syphilis infection in the UK, 2010-2011
n %
Maternal ethnic group (n=1348)
White 667 49
Black 436 32
Asian 188 14
Other 28 2
Mixed 29 2
Maternal region of birth (n=1266)
Europe 687 54
British Isles 377 30
Eastern Europe 268 21
Elsewhere in Europe 42 3
Africa 310 24
Asia 164 13
Other 105 8
Previous pregnancies (n=1292)
None 234 18
One 331 26
Two or more 727 56
Previous syphilis diagnosis (n=1384) a
No 374 27
Yes 1010 73
Other positive screening tests in pregnancy (n=1248) b
HIV 51 4
Hepatitis B virus 52 4
Hepatitis C virus 24 2
At least one of the above 115 9
Median (IQR)
Maternal age (n=1419) 31.4 (27.0, 35.5)
Years since arrival in the UK c (n=373) 5 (1, 9)
Years since previous syphilis diagnosis d (n=722) 4 (2, 7)
Gestation at antenatal booking (n=1271) 11.7 (9.9, 15.1)
a 41 women required treatment for syphilis in pregnancy, but it was unclear whether they
had been previously diagnosed (see Figure 1).
b Categories are not mutually exclusive; 12 women were reported to have two of the three
specified co-infections.
c At first antenatal appointment; year of arrival in the UK was only reported for 42%
(373/889) of women born abroad.
d At first antenatal appointment; year of diagnosis was only reported for 71% (722/1010) of
women with a previous syphilis diagnosis.
Table 2. Treatment details for 570 women requiring treatment for syphilis in pregnancy,
2010-2011
n %
Treated in pregnancy (n=537)
Yes 516 96
No a 21 4
Drugs (n=494)
Benzathine penicillin 439 89
Procaine penicillin 17 3
Erythromycin 15 3
Doxycycline 10 2
Unspecified/other drugs 13 3
Timing of treatment in pregnancy (n=456)
First or second trimester 373 82
Third trimester 83 18
Doses of benzathine penicillin (n=433)
One 66 15
Two 49 11
Three or more 318 73
a 10 women declined treatment, three delivered before their GUM appointment and three
were diagnosed at or after delivery; for the remaining four, no further information was
given.
